Oncology R&D, GlaxoSmithKline, Uxbridge, UK.
Cancer Imaging. 2010 Oct 4;10 Spec no A(1A):S74-82. doi: 10.1102/1470-7330.2010.9027.
Drug development continues to face challenges to successfully progress the most promising drug candidates through the stages of clinical trials. Given the increasing cost to develop a drug, methods are required to characterise early drug efficacy and safety. Imaging techniques are increasingly used in oncological clinical trials to provide evidence for decision making. With the application of conventional morphological imaging techniques and standardised response criteria based on tumour size measurements, imaging continues to be used to define key study end points. However, functional imaging techniques are likely to play an important role in the evaluation of novel therapeutics, although how these methods are to be optimally applied has yet to be clearly established. The specific challenges of standardising multi-centre imaging in the context of clinical trials are highlighted, including the processes for image acquisition, data analysis and radiological review.
药物研发在将最有前途的候选药物成功推进临床试验阶段方面仍然面临挑战。鉴于开发药物的成本不断增加,需要采用方法来早期评估药物的疗效和安全性。影像学技术在肿瘤学临床试验中越来越多地用于提供决策依据。应用常规形态影像学技术和基于肿瘤大小测量的标准化反应标准,影像学继续用于定义关键研究终点。然而,功能影像学技术可能在评估新型治疗方法方面发挥重要作用,尽管这些方法如何得到最佳应用尚未明确。突出强调了在临床试验中标准化多中心影像学所面临的具体挑战,包括图像采集、数据分析和放射学审查过程。